To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Cochrane Overview: Biologics more effective than placebo in treating rheumatoid arthritis

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
March 2013

Cochrane Overview: Biologics more effective than placebo in treating rheumatoid arthritis

Vol: 2| Issue: 2| Number:46| ISSN#: 2564-2537
Study Type:Meta analysis
OE Level Evidence:1
Journal Level of Evidence:N/A

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: A Cochrane overview

CMAJ. 2009 Nov 24;181(11):787-96. Epub 2009 Nov 2.

Contributing Authors:
JA Singh R Christensen GA Wells ME Suarez-Almazor R Buchbinder MA Lopez-Olivo ET Ghogomu P Tugwell

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

This network meta-analysis identified 6 Cochrane Collaboration systematic reviews, comprised in total of 31 studies. These reviews examined the safety and benefits of 6 biologics in patients with rheumatoid arthritis (abatacept, adalimumab, anakinra, etanercept, infliximab and rituximab). The primary outcomes of this study were safety (number of withdrawals related to adverse effects) and benefit ...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue